Literature DB >> 31168461

Advances in nanotechnology and asthma.

Lingwei Wang1, Mengjie Feng1, Qiuwen Li1, Chen Qiu1, Rongchang Chen1.   

Abstract

According to the World Health Organization, Asthma is the fastest-growing disease in the world alongside HIV/AIDS, and its socioeconomic burden exceeds the sum of HIV/AIDS and tuberculosis. Its high disability and mortality rates have become serious social and public health concerns. Asthma is a heterogeneous disease in which genetic polymorphisms interact with the environmental factors. While no specific treatment has been available for asthma due to its complex pathogenesis, the advances in nanotechnology have brought new hope for the early diagnosis, treatment, and prevention of asthma. Nanotechnology can achieve targeted delivery of drugs or genes, reduce toxic effects, and improve drug bioavailability. The nano-modifications of drugs and the development of new nano-drugs have become new research directions. Studies have demonstrated the safety and effectiveness of nanocarriers. However, many challenges still need to be overcome before nanotherapy can be applied in clinical practice. In this article we review the new research highlights in this area, with an attempt to explore the great potential and feasibility of nanotechnology in treating asthma.

Entities:  

Keywords:  Nanotechnology; asthma; nano-modifications of drug; nanotherapy; new nano-drugs

Year:  2019        PMID: 31168461      PMCID: PMC6526277          DOI: 10.21037/atm.2019.04.62

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  37 in total

1.  [The efficacy of half of the Global Initiative for Asthma recommended dose of inhaled corticosteroids in the management of Chinese asthmatics].

Authors:  Ping Chen; Hai-tao Zhao; Li Sun; Jiang-tao Lin; Hong-yu Zhang; Shao-guang Huang; Bao-yu Zhu; Kai-sheng Yin; Jing-ping Zheng; Wen-bing Xu; Hua-hao Shen; Qiang Li; Nan-shan Zhong
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2005-07

Review 2.  Pegasparaginase: where do we stand?

Authors:  Amer Zeidan; Eunice S Wang; Meir Wetzler
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

3.  An ATS/ERS report: 100 key questions and needs in occupational asthma.

Authors:  S M Tarlo; J-L Malo
Journal:  Eur Respir J       Date:  2006-03       Impact factor: 16.671

4.  Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo.

Authors:  M Köping-Höggård; I Tubulekas; H Guan; K Edwards; M Nilsson; K M Vårum; P Artursson
Journal:  Gene Ther       Date:  2001-07       Impact factor: 5.250

5.  In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers.

Authors:  C Rudolph; J Lausier; S Naundorf; R H Müller; J Rosenecker
Journal:  J Gene Med       Date:  2000 Jul-Aug       Impact factor: 4.565

6.  Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells.

Authors:  Thomas Merdan; Jon Callahan; Holger Petersen; Klaus Kunath; Udo Bakowsky; Pavla Kopecková; Thomas Kissel; Jindrich Kopecek
Journal:  Bioconjug Chem       Date:  2003 Sep-Oct       Impact factor: 4.774

7.  Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.

Authors:  Farhan Jalees Ahmad; Gaurav Mittal; Gaurav K Jain; Geena Malhotra; Roop K Khar; Aseem Bhatnagar
Journal:  Eur J Pharm Biopharm       Date:  2008-10-10       Impact factor: 5.571

8.  The characterization of novel polymeric paste formulations for intratumoral delivery.

Authors:  John K Jackson; Xichen Zhang; Stevyn Llewellen; William L Hunter; Helen M Burt
Journal:  Int J Pharm       Date:  2004-02-11       Impact factor: 5.875

Review 9.  Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.

Authors:  Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Future Oncol       Date:  2005-12       Impact factor: 3.404

10.  Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma.

Authors:  Mukesh Kumar; Xiaoyuan Kong; Aruna K Behera; Gary R Hellermann; Richard F Lockey; Shyam S Mohapatra
Journal:  Genet Vaccines Ther       Date:  2003-10-27
View more
  5 in total

1.  Nanotechnology as a savior in asthma management.

Authors:  Chin Kook Rhee
Journal:  Ann Transl Med       Date:  2019-10

2.  How will nanotechnology lead to better control of asthma?

Authors:  Bumhee Yang; Hayoung Choi; Sang-Heon Kim; Ho Joo Yoon; Hyun Lee
Journal:  Ann Transl Med       Date:  2019-10

Review 3.  Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives.

Authors:  Minhua Chen; Zhangxuan Shou; Xue Jin; Yingjun Chen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

Review 4.  Susceptibility Factors in Chronic Lung Inflammatory Responses to Engineered Nanomaterials.

Authors:  Dorothy J You; James C Bonner
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

Review 5.  Packaging and Delivery of Asthma Therapeutics.

Authors:  Bryan J Mathis; Misa Kusumoto; Alexander Zaboronok; Yuji Hiramatsu
Journal:  Pharmaceutics       Date:  2021-12-31       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.